Amgen Inc.-Product Pipeline Review-2015

Amgen Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC06904CDB
  • |
  • Pages: 238
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Amgen Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Amgen Inc.-Product Pipeline Review-2015', provides an overview of the Amgen Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Amgen Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Amgen Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Amgen Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Amgen Inc.'s pipeline products

Reasons To Buy

Evaluate Amgen Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Amgen Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Amgen Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Amgen Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Amgen Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Amgen Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Amgen Inc. Snapshot 7

Amgen Inc. Overview 7

Key Information 7

Key Facts 7

Amgen Inc.-Research and Development Overview 8

Key Therapeutic Areas 8

Amgen Inc.-Pipeline Review 16

Pipeline Products by Stage of Development 16

Pipeline Products-Monotherapy 17

Pipeline Products-Partnered Products 18

Pipeline Products-Out-Licensed Products 20

Amgen Inc.-Pipeline Products Glance 23

Amgen Inc.-Late Stage Pipeline Products 23

Amgen Inc.-Clinical Stage Pipeline Products 26

Amgen Inc.-Early Stage Pipeline Products 29

Amgen Inc.-Drug Profiles 33

blinatumomab 33

denosumab 36

evolocumab 39

ivabradine hydrochloride 42

talimogene laherparepvec 44

adalimumab biosimilar 47

bevacizumab biosimilar 48

brodalumab 49

cinacalcet hydrochloride 51

darbepoetin alfa (recombinant) 53

etelcalcetide 55

fulranumab 57

panitumumab 60

rilotumumab 63

rituximab biosimilar 65

romosozumab 66

trastuzumab biosimilar 68

trebananib 69

abrilumab 72

AMG-139 73

AMG-157 74

AMG-334 76

AMG-337 77

AMG-557 78

ganitumab 80

omecamtiv mecarbil 83

romiplostim 86

AMG-232 88

AMG-172 89

AMG-208 91

AMG-211 92

AMG-282 94

AMG-319 95

AMG-357 96

AMG-581 97

AMG-595 98

AMG-729 100

AMG-780 101

AMG-811 102

AMG-820 103

AMG-876 104

AMG-900 105

infliximab biosimilar 107

pasotuxizumab 108

solitomab 110

AM-1638 111

AM-6226 112

AM-7209 113

AM-8553 114

AM-9514 115

AMG-161 116

AMG-1694 117

AMG-330 118

AMG-3969 119

AMG-511 120

AMG-8718 121

AMG-925 122

Biosimilar 1 for Undisclosed Indication 123

Biosimilar 2 for Undisclosed Indication 124

Biosimilar 3 for Undisclosed Indication 125

Calcimimetic-18 126

cetuximab biosimilar 127

Drug to Antagonize ActRIIB for Cancer Cachexia 128

Drug to Inhibit PI3K Beta/Delta for Rheumatoid Arthritis 129

Drugs to Antagonize EP2 Receptor for Alzheimer Disease 130

Drugs to Inhibit BACE1 for Alzheimer Disease 131

Monoclonal Antibody Conjugated 1 for Cancer 132

Monoclonal Antibody Conjugated 2 for Cancer 133

Monoclonal Antibody for Multiple Myeloma 134

Monoclonal Antibody for Solid Tumors 135

morpholinone-27 136

MT-204 137

Recombinant Protein for Type 2 Diabetes 138

Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase Inhibitor for Obesity, Dyslipidemia and Type 2 Diabetes 139

Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase Inhibitor for Obesity Dyslipidemia and Type 2 Diabetes 140

Small Molecule to Agonize GPR119 for Undisclosed Indication 141

Small Molecule to Agonize GPR119 Receptor for Undisclosed Indication 142

Small Molecule to Agonize GPR142 for Type 2 Diabetes 143

Small Molecule to Inhibit Beta Secretase for Alzheimer's Disease 144

Small Molecule to Inhibit Gamma Secretase for Alzheimer's disease 145

Small Molecule to Inhibit PI3K Delta for Inflammation 146

Small Molecule to Inhibit PI3K/mTOR for Cancer 147

Small Molecules to Inhibit PDE10A for Neurological Diseases 148

AA-71 149

Drugs for Inflammatory Bowel Disease 150

Morpholinone-10 151

Morpholinone-16 152

Small Molecules to Inhibit CDC7 kinase for Cancer 153

Small Molecules to Inhibit Tankyrase for Cancer 154

Amgen Inc.-Pipeline Analysis 155

Amgen Inc.-Pipeline Products by Target 155

Amgen Inc.-Pipeline Products by Route of Administration 160

Amgen Inc.-Pipeline Products by Molecule Type 161

Amgen Inc.-Pipeline Products by Mechanism of Action 162

Amgen Inc.-Recent Pipeline Updates 166

Amgen Inc.-Dormant Projects 212

Amgen Inc.-Discontinued Pipeline Products 215

Discontinued Pipeline Product Profiles 216

Amgen Inc.-Company Statement 221

Amgen Inc.-Locations And Subsidiaries 223

Head Office 223

Other Locations & Subsidiaries 223

Amgen Inc.-Key Manufacturing Facilities 230

Appendix 231

Methodology 231

Coverage 231

Secondary Research 231

Primary Research 231

Expert Panel Validation 231

Contact Us 231

Disclaimer 232

List of Tables

Amgen Inc., Key Information 13

Amgen Inc., Key Facts 13

Amgen Inc.-Pipeline by Indication, 2015 15

Amgen Inc.-Pipeline by Stage of Development, 2015 22

Amgen Inc.-Monotherapy Products in Pipeline, 2015 23

Amgen Inc.-Partnered Products in Pipeline, 2015 24

Amgen Inc.-Partnered Products/ Combination Treatment Modalities, 2015 25

Amgen Inc.-Out-Licensed Products in Pipeline, 2015 26

Amgen Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2015 27

Amgen Inc.-Pre-Registration, 2015 29

Amgen Inc.-Filing rejected/Withdrawn, 2015 30

Amgen Inc.-Phase III, 2015 31

Amgen Inc.-Phase II, 2015 32

Amgen Inc.-Phase I, 2015 33

Amgen Inc.-Preclinical, 2015 35

Amgen Inc.-Discovery, 2015 38

Amgen Inc.-Pipeline by Target, 2015 162

Amgen Inc.-Pipeline by Route of Administration, 2015 166

Amgen Inc.-Pipeline by Molecule Type, 2015 167

Amgen Inc.-Pipeline Products by Mechanism of Action, 2015 169

Amgen Inc.-Recent Pipeline Updates, 2015 172

Amgen Inc.-Dormant Developmental Projects,2015 218

Amgen Inc.-Discontinued Pipeline Products, 2015 221

Amgen Inc., Other Locations 229

Amgen Inc., Subsidiaries 232

Amgen Inc., Key Manufacturing Facilities 236

List of Figures

Amgen Inc.-Pipeline by Top 10 Indication, 2015 15

Amgen Inc.-Pipeline by Stage of Development, 2015 22

Amgen Inc.-Monotherapy Products in Pipeline, 2015 23

Amgen Inc.-Partnered Products in Pipeline, 2015 24

Amgen Inc.-Out-Licensed Products in Pipeline, 2015 26

Amgen Inc.-Pipeline by Top 10 Target, 2015 161

Amgen Inc.-Pipeline by Top 10 Route of Administration, 2015 166

Amgen Inc.-Pipeline by Top 10 Molecule Type, 2015 167

Amgen Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 168

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Amgen Inc.; Amgen Inc. - Key Therapeutics; Amgen Inc. - Pipeline Overview and Promising Molecules; Amgen Inc. - News; Amgen Inc. - Latest Updates; Amgen Inc. - Pipeline; Amgen Inc. - Discontinued/Dormant Projects

select a license
Single User License
USD 1500 INR 107685
Site License
USD 3000 INR 215370
Corporate User License
USD 4500 INR 323055



I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]